In the SARS-CoV-2-negative group, there were higher rates of asthma (19.79% vs. 15.44%, p = 0.039), previous influenza vaccinations (15.96% vs. 9.26%, p = 0.0003), and somatotropin treatment (8.62% vs. 5.23%, p = 0.020). Here, GH1 is linked to asthma.